{
  "drug_name": "Hydroxychloroquine",
  "url": "https://wikem.org/wiki/Hydroxychloroquine",
  "scraped_at": "2026-01-10T07:55:00.862176",
  "sections": {
    "Administration": {
      "text": "Type:\nAntimalarial\n, anti-inflammatory\nDosage Forms:\nRoutes of Administration: Oral\nCommon Trade Names: Plaquenil",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antimalarial",
          "url": "https://wikem.org/wiki/Antimalarial"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Malaria": {
          "text": "Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [\nCDC malaria information by country\n] for details\nMalaria treatment: 800 mg PO, then 400 mg PO at 6, 24, and 48 hours after initial dose\nMalaria prophylaxis: 400 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure",
          "tables": []
        },
        "Other_indications": {
          "text": "Lupus\n: 200-400mg PO 1-2 times per day\nRheumatoid Arthritis\n: 200-600mg PO daily",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Lupus",
          "url": "https://wikem.org/wiki/Lupus"
        },
        {
          "text": "Rheumatoid Arthritis",
          "url": "https://wikem.org/wiki/Rheumatoid_Arthritis"
        }
      ]
    },
    "Malaria": {
      "text": "Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [\nCDC malaria information by country\n] for details\nMalaria treatment: 800 mg PO, then 400 mg PO at 6, 24, and 48 hours after initial dose\nMalaria prophylaxis: 400 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure",
      "subsections": {
        "Other_indications": {
          "text": "Lupus\n: 200-400mg PO 1-2 times per day\nRheumatoid Arthritis\n: 200-600mg PO daily",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Lupus",
          "url": "https://wikem.org/wiki/Lupus"
        },
        {
          "text": "Rheumatoid Arthritis",
          "url": "https://wikem.org/wiki/Rheumatoid_Arthritis"
        }
      ]
    },
    "Other_indications": {
      "text": "Lupus\n: 200-400mg PO 1-2 times per day\nRheumatoid Arthritis\n: 200-600mg PO daily",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Lupus",
          "url": "https://wikem.org/wiki/Lupus"
        },
        {
          "text": "Rheumatoid Arthritis",
          "url": "https://wikem.org/wiki/Rheumatoid_Arthritis"
        }
      ]
    },
    "Pediatric_Dosing": {
      "text": "Malaria treatment: 12.9 mg/kg (max 800mg) PO, then 6.45 mg/kg PO at 6, 24, and 48 hours after initial dose\nMalaria prophylaxis: 6.45 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: D\nLactation risk\n: Infant risk minimal\nRenal dosing:\nHepatic dosing:",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nRetinal or visual field changes from prior 4-aminoquinoline compound\nProlonged use in children",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Torsades de pointes\nAgranulocytosis, leukopenia, thrombocytopenia, aplastic anemia\nFulminant hepatic failure\nMyopathy\nSeizure\nRetinopathy\nHearing loss\nAngioedema",
          "tables": []
        },
        "Common": {
          "text": "Corneal disorder",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Torsades de pointes\nAgranulocytosis, leukopenia, thrombocytopenia, aplastic anemia\nFulminant hepatic failure\nMyopathy\nSeizure\nRetinopathy\nHearing loss\nAngioedema",
      "subsections": {
        "Common": {
          "text": "Corneal disorder",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "Corneal disorder",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 7-50 days\nMetabolism: Hepatic\nExcretion: Mostly renal",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Precise mechanism unknown",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Antimalarial medications\nMalaria",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antimalarial medications",
          "url": "https://wikem.org/wiki/Antimalarial_medications"
        },
        {
          "text": "Malaria",
          "url": "https://wikem.org/wiki/Malaria"
        }
      ]
    }
  }
}